Lung Cancer Awareness Month

A study published by the New England Journal of Medicine of the head-to-head FLAME study, compared the efficacy of once-daily LABA-LAMA (indacaterol/glycopyrronium bromide) to twice-daily ICS-LABA (salmeterol/ fluticasone [SFC]) in reducing Chronic Obstructive Pulmonary Disease (COPD) exacerbations.

The published FLAME results are anticipated to impact the future management and treatment of COPD patients. Preventing exacerbations is one of the primary goals of long-term care for COPD patients.

These episodes have a detrimental effect on quality of life and disease progression, contributing to further lung function decline and in severe cases, hospitalisation.

---

Study confirms LABA/LAMA dual bronchodilator good for preventing COPD exacerbations

---

Speaking on the study Dr Paramjyothi, Professor and Head, Dept. of Respiratory Medicine, NIMS said, “Reducing exacerbations in COPD patients is vital to improve the outcomes and quality of life of the patient.

The superiority of a once daily LABA/LAMA dual bronchodilator combination to the currently used inhaled corticosteroid has been proven in the study and has also shown to be more effective in reducing exacerbations.

The FLAME will be a beacon of light to patients with COPD and will provide a new benchmark in the treatment of patients with COPD.”